13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q2 2018. See the latest, Q3 2026 →

Reported value

$11.44B

+10% on the quarter before

Positions

33

6 new, 6 sold out

Top 10

76.7%

of the value

Est. gain

+$752.0M

on stocks held all quarter

Est. return

+8.7%

on those stocks since Q1 2018

Filed

Aug 13, 2018

On SEC EDGAR ↗

Positions as of Jun 30, 2018, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2018. Striped tiles are options.

Twenty First Centy Fox Inc17%
Synchrony Finl8.5%
Cheniere Energy Inc8.1%
Viasat Inc7.9%
Qorvo7.7%
Allergan Plc7.2%
Pioneer Nat Res Co6.6%
Twenty First Centy Fox Inc5.9%
Antero Res Corp5.0%
Colony Cap Inc New2.7%
Tesla2.7%AT&T2.7%
Cardinal Health Inc2.2%
Atara Biotherapeutics Inc2.0%
Mckesson Corp1.9%
Theravance Biopharma Inc1.8%
9 others1.8%
Pg&E Corp1.7%
Amerisourcebergen Corp1.4%
Veritiv Corp1.3%
Tribune Media Co1.0%
0.8%
0.7%
0.7%
0.5%

Largest buys

Since Q1 2018, sized at quarter-end prices.

  1. Twenty First Centy Fox Inc~$637.4MAdded, 9.4% → 17.1% of the portfolio+12,827,098 shares
  2. Colony Cap Inc New~$310.0MNew, 0.0% → 2.7% of the portfolio+49,687,370 shares
  3. AT&T~$304.4MNew, 0.0% → 2.7% of the portfolio+9,480,700 shares
  4. Tesla~$245.0MAdded, 0.5% → 2.7% of the portfolio+200,000,000 shares
  5. Tribune Media Co~$114.7MNew, 0.0% → 1.0% of the portfolio+2,996,042 shares
  6. Twenty First Centy Fox Inc~$107.1MAdded, 4.0% → 5.9% of the portfolio+2,172,902 shares
  7. Sinclair Broadcast Group Inc~$82.7MNew, 0.0% → 0.7% of the portfolio+2,571,302 shares
  8. Pg&E Corp~$57.5MAdded, 1.3% → 1.7% of the portfolio+1,350,028 shares
  9. Amerisourcebergen Corp~$47.4MAdded, 1.1% → 1.4% of the portfolio+556,349 shares
  10. Allergan Plc~$33.3MAdded, 7.7% → 7.2% of the portfolio+200,000 shares

Largest sells

Since Q1 2018, sized at quarter-end prices.

  1. Time Warner Inc~$766.1MSold out, 7.4% → 0.0% of the portfolio−8,100,000 shares
  2. Cheniere Energy Inc~$425.7MCut, 10.7% → 8.1% of the portfolio−6,530,205 shares
  3. Colony Northstar Inc~$279.2MSold out, 2.7% → 0.0% of the portfolio−49,687,370 shares
  4. Pbf Energy Inc~$268.6MSold out, 2.6% → 0.0% of the portfolio−7,924,175 shares
  5. ChipMOS Technologies~$14.8MSold out, 0.1% → 0.0% of the portfolio−933,658 shares
  6. Forward Pharma A/S~$6.2MSold out, 0.1% → 0.0% of the portfolio−2,848,003 shares
  7. Orexigen Therapeutics Inc~$465,000Sold out, 0.0% → 0.0% of the portfolio−2,226,839 shares

Holdings

As of Jun 30, 2018; changes in shares since Mar 31, 2018.

Positions, sorted by share of the portfolio
HoldingValue
Twenty First Centy Fox IncCL A · shares +48% · price +35.4%17.1%$1.96B+$345.7M
Synchrony FinlCOM · shares 0% · price −0.4%8.5%$977.9M−$4.4M
Cheniere Energy IncCOM NEW · shares −32% · price +22.0%8.1%$925.4M+$166.7M
Viasat IncCOM · shares +0.5% · price +0.0%7.9%$902.5M+$252.04
QorvoCOM · shares 0% · price +13.8%7.7%$881.9M+$106.9M
Allergan PlcSHS · shares +4.2% · price −0.9%7.2%$825.3M−$7.5M
Pioneer Nat Res CoCOM · shares 0% · price +10.2%6.6%$757.0M+$69.8M
Twenty First Centy Fox IncCL B · shares +19% · price +35.5%5.9%$670.4M+$147.5M
Antero Res CorpCOM · shares 0% · price +7.6%5.0%$567.6M+$39.9M
Colony Cap Inc NewCL A COM · shares New2.7%$310.0M—
TeslaNOTE 2.375% 3/1 · shares +400% · price +17.4%2.7%$306.3M—
AT&TCOM · shares New2.7%$304.4M—
Cardinal Health IncCOM · shares 0% · price −22.1%2.2%$249.0M−$70.6M
Atara Biotherapeutics IncCOM · shares 0% · price −5.8%2.0%$229.9M−$14.1M
Mckesson CorpCOM · shares +0.7% · price −5.3%1.9%$217.1M−$12.1M
Theravance Biopharma IncCOM · shares 0% · price −6.5%1.8%$211.1M−$14.6M
Pg&E CorpCOM · shares +43% · price −3.1%1.7%$191.5M−$4.3M
Amerisourcebergen CorpCOM · shares +42% · price −1.1%1.4%$159.8M−$1.2M
Veritiv CorpCOM · shares 0% · price +1.7%1.3%$152.4M+$2.5M
Tribune Media CoCL A · shares New1.0%$114.7M—
Keryx Biopharmaceuticals IncCOM · shares 0% · price −8.1%0.85%$97.0M−$8.5M
Sinclair Broadcast Group IncCL A · shares New0.72%$82.7M—
Amc Entmt Hldgs IncCL A COM · shares 0% · price +13.2%0.70%$79.5M+$9.2M
Novagold Res IncCOM NEW · shares 0% · price +2.8%0.52%$59.9M+$1.6M
Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price +0.8%0.40%$45.9M+$352,000
Total 33 positions100%$11.44B+$752.0M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2018 to Q2 2018: 25 stocks held throughout, up $752.0M (+8.7%).

  1. Twenty First Centy Fox Inc+$345.7M+35%
  2. Cheniere Energy Inc+$166.7M+22%
  3. Twenty First Centy Fox Inc+$147.5M+35%
  4. Qorvo+$106.9M+14%
  5. Pioneer Nat Res Co+$69.8M+10%
  6. Keryx Biopharmaceuticals Inc−$8.5M−8%
  7. Mckesson Corp−$12.1M−5%
  8. Atara Biotherapeutics Inc−$14.1M−6%
  9. Theravance Biopharma Inc−$14.6M−6%
  10. Cardinal Health Inc−$70.6M−22%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free